Sleep Deprivation and Advancement of Sleep Period as Treatment for Bipolar Depression.

Sleep Deprivation and Three Days Sleep Phase Advancement as Treatment for Bipolar Depression.

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00229151

Enrollment

Registered

2005-09-29

Start date

2005-10-31

Completion date

2011-12-31

Last updated

2012-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder

Brief summary

The purpose of this study is to determine if sleep deprivation and sleep phase advancement is effective treatment of bipolar patients in a depressive phase.

Detailed description

Background: The onset of therapeutic action for most anti-depressive treatments is usually two weeks. During this period patients suffer from great symptomatic distress. Treatment options that are effective in this period is therefore of interest for psychiatric wards. Aim: To explore if sleep deprivation and three days sleep phase advancement is effective treatment for inpatients with bipolar disorder in a depressive phase. Method: A randomized controlled trial with 24 patients diagnosed with bipolar disorder. Patients will be randomized to treatment as usual in an psychiatric ward, or sleep deprivation and three days sleep phase advancement. Patients in the treatment as usual group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria.

Interventions

BEHAVIORALSleep deprivation and sleep phase advancement

Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.

OTHERusual treatment

Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Bipolar disorder, depressive phase

Exclusion criteria

* substance abuse, psychotic symptoms, suicidal intentions, active mania/hypomania.

Design outcomes

Primary

Measure	Time frame
Scores on rating scales for depression and symptom severity.	one month

Secondary

Measure	Time frame
Scores on rating scales for anxiety, mania, cognitive processing, and sleep quality.	one month

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026